Key result
This document is the editorial board and publication information page for an issue of Seminars in Neurology on muscular dystrophies, containing no clinical trial data.
This review highlights recent advances in the diagnosis, genetic understanding, and therapeutic approaches for muscular dystrophies.
Answers are grounded in this paper and cite their sources.
No trial data here on muscular dystrophies; leaves open the clinical impact of recent diagnostic and therapeutic advances.
The muscular dystrophies are disorders of progressive muscular degeneration and weakness. As a group they display clinical heterogeneity that reflects the heterogeneity of molecular mechanisms responsible for them, and range from congenital to adulthood onset. Recent advances in the field include improved methods of diagnosis, continued identification of disease genes, and the development of a unified model of pathogenesis in facioscapulohumeral dystrophy. These advances are reflected in the development of new therapeutic approaches, some of which have already led to clinical trials in the dystrophinopathies and limb-girdle dystrophies.
No takes yet. Share an insight, caveat, or question.
Kevin M. Flanigan (2012) studied Muscular Dystrophies. This document is the editorial board and publication information page for an issue of Seminars in Neurology on muscular dystrophies, containing no clinical trial data.
Synapse has enriched 10 related papers. Consider them for comparative context: